Connect Biopharma Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation
Reuters
Sep 03
<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a> Unveils Rademikibart's Promising Potential for Asthma and COPD Treatment in Latest Presentation
Connect Biopharma Holdings Ltd. has released a corporate presentation detailing its recent advancements and strategic focus areas. The company is advancing its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeted at eosinophilic-driven respiratory diseases. Rademikibart is positioned as a promising option for the treatment of acute exacerbations in asthma and COPD, with market research highlighting its potential advantage over existing biologics like dupilumab. The company has initiated parallel Phase 2 studies for this purpose, with topline data expected in the first half of 2026. Connect Biopharma holds global development and commercialization rights for Rademikibart outside of greater China. The company anticipates significant commercial opportunities, with projected worldwide peak sales exceeding $3 billion for asthma and $2 billion for COPD. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.